Document is current
Any future updates will be listed below
-
Authors
Mäkelä, Anna R.
Uğurlu, Hasan https://orcid.org/0000-0002-3849-7847
Hannula, Liina
Kant, Ravi https://orcid.org/0000-0003-3878-9775
Salminen, Petja
Fagerlund, Riku
Mäki, Sanna
Haveri, Anu https://orcid.org/0000-0003-4620-7536
Strandin, Tomas
Kareinen, Lauri
Hepojoki, Jussi https://orcid.org/0000-0001-5699-214X
Kuivanen, Suvi
Levanov, Lev
Pasternack, Arja https://orcid.org/0000-0002-6088-4245
Naves, Rauno A.
Ritvos, Olli
Österlund, Pamela https://orcid.org/0000-0002-2229-6661
Sironen, Tarja https://orcid.org/0000-0002-2344-2755
Vapalahti, Olli https://orcid.org/0000-0003-2270-6824
Kipar, Anja https://orcid.org/0000-0001-7289-3459
Huiskonen, Juha T. https://orcid.org/0000-0002-0348-7323
Rissanen, Ilona https://orcid.org/0000-0003-4937-1825
Saksela, Kalle https://orcid.org/0000-0003-0827-122X
-
Funding
Funding for this research was provided by:
Academy of Finland (331787)
- License Information
-
More Information
Article History
Received: 22 December 2022
Accepted: 10 March 2023
First Online: 24 March 2023
Competing interests
: K.S. is a founder and shareholder of Next Biomed Therapies Oy that develops SH3 scaffold targeting technologies. ARM is a founder and shareholder of the start-up Pandemblock Oy that has acquired commercial rights for TriSb92. The authors are inventors of the related patents/applications WO2017009533 (K.S.) and PCT/FI2022/050764 (K.S. and A.R.M.). The other authors have no competing interests to declare.
